Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/ACI.0000000000000995 | DOI Listing |
Viruses
November 2024
Institute of Medical Virology, Justus Liebig University Giessen, 35392 Giessen, Germany.
The COVID-19 pandemic, along with the emergence and sustained transmission of highly pathogenic avian influenza viruses (H5N1) in U [...
View Article and Find Full Text PDFInt J Mol Sci
December 2024
Department of Pathology and Laboratory Medicine, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Urologic cancers exhibit tumor heterogeneity in their morphology, gene expression, and phenotypic features, and have different responses to drug treatment [...
View Article and Find Full Text PDFWorld J Clin Cases
January 2025
Department of Neurology, Guizhou Medical University, Guiyang 550004, Guizhou Province, China.
Dementia is a group of diseases, including Alzheimer's disease (AD), vascular dementia, Lewy body dementia, frontotemporal dementia, Parkinson's disease dementia, metabolic dementia and toxic dementia. The treatment of dementia mainly includes symptomatic treatment by controlling the primary disease and accompanying symptoms, nutritional support therapy for repairing nerve cells, psychological auxiliary treatment, and treatment that improves cognitive function through drugs. Among them, drug therapy to improve cognitive function is important.
View Article and Find Full Text PDFJ Clin Transl Endocrinol
December 2024
Department of Medical and Surgical Sciences (DIMEC), University of Bologna, 40138 Bologna, Italy.
Thanks to the identification of crucial molecular pathways, the therapeutic landscape for advanced differentiated thyroid tumors (DTCs) has significantly improved during the last ten years. The therapeutic scenario has been greatly impacted by the discovery of mutually exclusive gene changes in the MAPK and PI3K/AKT pathways, such as or fusions and pathogenic mutations of the and genes. Indeed, multi-kinase inhibitors and selective inhibitors have demonstrated outstanding efficacy for radioactive iodine-refractory (RAI-R) drug treatment, with overall response rates reaching up to 86%.
View Article and Find Full Text PDFFront Immunol
January 2025
Translational Radiobiology Lab, Department of Radiotherapy and Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Background: Esophageal cancer has a poor prognosis despite treatment advancements. Although the benefit of neoadjuvant chemoradiotherapy (CRT) followed by adjuvant immunotherapy is evident, the effects of CRT on PD-L1 expression in esophageal cancer are not well understood. This study examines the impact of neoadjuvant CRT on PD-L1 surface expression in esophageal cancer both and considering its implications for immunotherapy.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!